The new guidance includes updates on diabetes technology use, GLP-1 receptor agonists, liver disease, drinking water, and ...

Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and ...

The American Diabetes Association has released the Standards of Care in Diabetes-2025, the authoritative guide for ...

Today, the American Diabetes Association® released the Standards of Care in Diabetes—2025 (Standards of Care) the gold ...

Earlier at ADA, Lilly reported phase 2 results with its once-daily oral GLP-1 agonist orforglipron, which achieved a weight reduction of almost 15% at 24 weeks, potentially giving Lilly the option ...

The ADA also recommended that if Ozempic and Wegovy are unavailable ... especially as shortages of branded GLP-1 drugs continue.

CGM Use, GLP-1s, Drinking Water Key of 2025 ADA Standards The new guidance includes updates on diabetes technology use, GLP-1 receptor agonists, liver disease, drinking water, and much more.

and prescription services for GLP-1 agonist medicines. The new financing will go towards expanding the company's services beyond home market Sweden – where it is already profitable – into new ...

The partnership between Ro and Eli Lilly (LLY) to streamline access to Lilly’s GLP-1 Zepbound single-dose vials for Ro patients with obesity is ...

A recent survey highlighted a significant interest in personalized dosing, which is expected to drive consumer demand, as it may alleviate side effects for those using compounded GLP-1 medications.